Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.8 GBX | -2.66% | -5.88% | +41.44% |
May. 01 | Poolbeg Pharma Secures Full Patent in US for Immunomodulator II | MT |
May. 01 | Poolbeg Pharma celebrates full patent approval for Immunomodulator II | AN |
Sales 2023 | - | Sales 2024 * | - | Capitalization | 64M 81.01M |
---|---|---|---|---|---|
Net income 2023 | -3M -3.8M | Net income 2024 * | -6M -7.59M | EV / Sales 2023 | - |
Net cash position 2023 * | 10.77M 13.63M | Net cash position 2024 * | 6.2M 7.85M | EV / Sales 2024 * | - |
P/E ratio 2023 |
-11.5
x | P/E ratio 2024 * |
-9.85
x | Employees | 12 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 77.34% |
1 day | -2.66% | ||
1 week | -5.88% | ||
Current month | +6.22% | ||
1 month | +29.95% | ||
3 months | +12.28% | ||
6 months | +31.28% | ||
Current year | +41.44% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 21-04-30 | |
Ian O'Connell
DFI | Director of Finance/CFO | 37 | 20-12-31 |
Carol Dalton
IRC | Investor Relations Contact | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Luke O'Neill
BRD | Director/Board Member | 60 | - |
Chief Executive Officer | 53 | 21-04-30 | |
Cathal Friel
FOU | Founder | 59 | 20-08-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 12.8 | -2.66% | 2,084,249 |
24-05-15 | 13.15 | -2.95% | 692,157 |
24-05-14 | 13.55 | 0.00% | 439,570 |
24-05-13 | 13.55 | -1.45% | 2,015,339 |
24-05-10 | 13.75 | +1.10% | 2,021,842 |
Delayed Quote London S.E., May 16, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+41.44% | 81.09M | |
+8.29% | 114B | |
+10.21% | 104B | |
+0.41% | 22.28B | |
-11.90% | 22.41B | |
-5.99% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- POLB Stock